MPM has collected three China drugs for its ‘best of both worlds’ strategy
MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three drug programs ...
Ansbert Gadicke, managing partner at MPM BioImpact and executive chair of K2 April 29, 2026 07:00 AM EDT StartupsDealsChina MPM has collected three China drugs so far for its ‘best of both worlds’ strategy Kyle LaHucik Biotech Correspondent MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that